MedDataX Logo

To Demonstrate the Relative Bioequivalence of Cefdinir and Omnicel 300 mg Capsule Fed Conditions

NCT ID: NCT00882154

Last Updated: 2017-03-29

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE1

Total Enrollment

28 participants

Study Classification

INTERVENTIONAL

Study Start Date

2005-04-30

Study Completion Date

2005-04-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

To demonstrate the relative bioequivalence of Cefdinir and Omnicel 300 mg capsule fed conditions.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

To Demonstrate the Relative Bioequivalence of Cefdinir and Omnicef 300 mg Capsule Fasting Conditions

NCT00882700

Healthy
COMPLETED PHASE1

To Demonstrate the Relative Bioequivalence of Cefdinir and Omnicel 250 mg/5 ml Oral Suspension Fed Conditions

NCT00883883

Healthy
COMPLETED PHASE1

To Demonstrate the Relative Bioequivalence of Cefdinir and Omnicel 250mg/5 ml Oral Suspension Fasting Conditions

NCT00882570

Healthy
COMPLETED PHASE1

Cross-over Study to Prove Bioequivalence Between Two Brands of Cefalexin Capsules

NCT01073553

Anti-Infective Agents
COMPLETED PHASE1

A Study of Cephalexin Capsules in Healthy Participants

NCT02123446

Healthy Volunteers
COMPLETED PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Healthy

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

CROSSOVER

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

1

Cefdinir 300 mg Capsule (Sandoz, Austria)

Group Type EXPERIMENTAL

Cefdinir 300 mg Capsule (Sandoz, Austria)

Intervention Type DRUG

2

Omnicef Cefdinir 300 mg Capsule (Abbott Laboratories, USA)

Group Type ACTIVE_COMPARATOR

Omnicef Cefdinir 300 mg Capsule (Abbott Laboratories, USA)

Intervention Type DRUG

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Cefdinir 300 mg Capsule (Sandoz, Austria)

Intervention Type DRUG

Omnicef Cefdinir 300 mg Capsule (Abbott Laboratories, USA)

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* No clinically significant abnormal finding on physical exam, medical history, or clinical laboratory results on screening.

Exclusion Criteria

* Positive test results for HIV or hepatitis B or C.
* Treatment for drug or alcohol dependence.
Minimum Eligible Age

18 Years

Maximum Eligible Age

56 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Sandoz

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Sandoz Inc.

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Richard Larouche, M.D.

Role: PRINCIPAL_INVESTIGATOR

SFBC Anapharm

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

50039

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Cefadroxil 500 mg Capsules in Normal Healthy Non-Smoking Male and Female Subjects.
NCT00835081 COMPLETED PHASE1
Bioequivalence Study Between SKF101804 Cefixime 200 Milligram (mg)/5 Milliliter (mL) Suspension Versus Cefixime 200 mg/5 mL Suspension Reference Product in Healthy Adult Subjects Under Fasting Conditions
NCT03408392 COMPLETED PHASE1
A Study of Cephalexin in Healthy Participants
NCT02100826 COMPLETED PHASE1
To Demonstrate the Relative Bioavailability of Cefzil 500 mg Cefprozil Tablets Under Fed Conditions
NCT00881855 COMPLETED PHASE1
A Study of Cephalexin Suspension in Healthy Participants
NCT02123459 COMPLETED PHASE1
Bioequivalence Study of Cephalexin Suspension 250
NCT01767571 COMPLETED PHASE1
Cross-over Study to Prove Bioequivalence Between Two Brands of Cefalexin Suspension
NCT01073540 COMPLETED PHASE1
A Bioequivalence Study of SKF101804 Cefixime Versus Cefixime Reference Formulation in Healthy Adults Under Fasting Conditions
NCT03329547 WITHDRAWN PHASE1
Bioequivalecne Study of Minocycline 100mg Tablets Under Fed Conditions
NCT00777413 COMPLETED NA
Bioequivalence Minocycline Bioequivalence
NCT01755611 COMPLETED PHASE1
Bioequivalence Study of Cephalexin Suspension 125
NCT01767532 COMPLETED PHASE1
Cefadroxil 500 mg Capsules Under Fasting Conditions
NCT00834275 COMPLETED PHASE1
A Study of Cephalexin Liquid for Pediatrics in Healthy Adults Participants
NCT02123472 COMPLETED PHASE1
Cross Over Study to Prove Bioequivalence Between Two Brands of Cefalexin Suspension
NCT01105208 COMPLETED PHASE1
A Study of Cephalexin Liquid in Healthy Participants
NCT02490670 COMPLETED PHASE1
To Demonstrate the Relative Bioavailability of Cefzil 250 mg/5 ml Cefprozil Oral Suspension Fed Conditions
NCT00881400 COMPLETED PHASE1
Clindamycin 300 mg Capsules in Healthy Subjects Under Fed Conditions
NCT00836004 COMPLETED PHASE1
Bioequivalence Study of Minocycline 100mg Tablets Under Fasting Conditions
NCT00776542 COMPLETED NA
Bioequivalence Study of Cephalexin Tablets 1g
NCT01767584 COMPLETED PHASE1
Bioequivalence Study Between Two Oral Formulations of Gemfibrozil Tablets
NCT00800475 COMPLETED PHASE1
Bioequivalence Study of Cefprozil 250 mg/ 5mL Powder For Oral Suspension Under Fasting Conditions
NCT00778557 COMPLETED NA
Bioavailability of Oseltamivir Phosphate 75 mg With Regards to Reference Product
NCT05083325 COMPLETED PHASE1
To Demonstrate the Relative Bioavailability of Cefzil 500 mg Cefprozil Tablets Under Fasting Conditions
NCT00881426 COMPLETED PHASE1
Minocycline Bioequivalence Study
NCT01938508 COMPLETED PHASE1
Two Way Bioequivalence Study Under Fed Conditions
NCT01217801 COMPLETED PHASE1